Aescap Life Sciences Newsletter Q3 2022

Upward potential of portfolio further increased. The fund made a small positive net performance for the third quarter of 1,8%. Continuous poor market sentiment continued to depress share prices of our portfolio companies despite the present and expected future revenue and profit growth these innovative companies face.

Aescap Life Sciences Newsletter Q3 2022